GP1BA and neoplasm: Primary tumor growth was monitored, and when tumors reached ~500 mm3 in size, anti-GPIbα or rat IgG was injected into platelet-depleted or control mice, respectively, every 3 days until 24 days post-injection (Figure 1A).